• 15 January 2012

    NovAliX and Teijin Pharma strike drug discovery alliance

    NovAliX SAS has entered into a multitarget integrated drug discovery collaboration with Tokyo-based Teijin Pharma to develop novel drug candidates against multiple targets across different therapeutic areas.

  • 12 January 2012

    CSL Behring begins phase II/III haemophilia study

    CSL Behring has initiated a global phase II/III, multi-centre study, designed to investigate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

  • 11 January 2012

    Spherix concludes SPX-106 drug toxicology study

    Spherix, a developer of proprietary therapeutic products for the treatment of diabetes, metabolic syndrome and atherosclerosis, has successfully completed the 28-day rat toxicology study of its drug candidate SPX-106.


Go Top